Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair deficient colorectal cancer - Supplementary Tables

Table S1: Search strategy for Embase Database: Embase 1974 to July 12, 2019Search executed on July 15, 2019<br>Table S2: Search strategy for MEDLINEDatabases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Daily and Versions(R) 1946 to July 12, 2019Search executed on July 15, 2019<br>Table S3: Search strategy for CENTRALDatabase(s): EBM Reviews - Cochrane Central Register of Controlled Trials October 2019 Search executed on July 15, 2019<br>Table S4: Search strategy for Embase - UpdateDatabase: Embase 1974 to April 27, 2020Search executed: April 28, 2020<br><br>Table S5: Search strategy for MEDLINEDatabases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Daily and Versions(R) 1946 to April 27, 2020Search executed: April 28, 2020<br><br>Table S6: Search strategy for CENTRALDatabase(s): EBM Reviews - Cochrane Central Register of Controlled Trials March 2020 Search executed on April 28, 2020<br><br>Table S7: Eligibility criteria from trials included in systematic reviewTable S8: Patient characteristics from trials included in systematic review<br>Table S9: Outcomes from trials included in systematic review<br>Table S10: Proportional hazard assumption test (Grambsch and Therneau test) of trials included in the analysisTable S11: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; no adjustment for crossover in KEYNOTE-177<br>Table S12: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using 2-stage model<br>Table S13: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model<br>Table S14: Estimated constant hazard ratios of progression-free survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis<br>Table S15: Estimated time-varying hazard ratios of overall survival with pembrolizumab versus competing interventions from random-effect network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model<br>Table S16: Odds ratios estimated from fixed-effect network meta-analysis for treatment-related Grade 3+ adverse events<br>